Search

Your search keyword '"Marchei E"' showing total 97 results

Search Constraints

Start Over You searched for: Author "Marchei E" Remove constraint Author: "Marchei E" Database MEDLINE Remove constraint Database: MEDLINE
97 results on '"Marchei E"'

Search Results

1. The prevalence and changes of alcohol consumption across three trimesters of pregnancy assessed by ethyl glucuronide concentration in maternal hair and self-reports: a cross-sectional study.

2. Prevalence of Psychoactive Substance Use During Pregnancy in Argentine Women: A Pilot Study Testing Maternal Hair.

3. NPS-EQA PART I: Four years' experience in external quality assessment program in Italy for classical and new psychoactive substances analysis in oral fluid.

4. NPS-EQA PART II: Four years' experience in external quality assessment program in Italy for classical and new psychoactive substances analysis in hair.

5. OILVEQ: an Italian external quality control scheme for cannabinoids analysis in galenic preparations of cannabis oil.

6. Metabolic profile of N-ethylhexedrone, N-ethylpentedrone, and 4-chloromethcathinone in urine samples by UHPLC-QTOF-HRMS.

7. Alcohol Consumption Assessed by a Biomarker and Self-Reported Drinking in a Sample of Pregnant Women in the South of Europe: A Comparative Study.

8. Assessment of alcohol consumption in mexican pregnant women by hair testing of ethyl glucuronide.

9. The recurrent pathogenic Pro890Leu substitution in CLTC causes a generalized defect in synaptic transmission in Caenorhabditis elegans .

10. GC-MS/MS Determination of Synthetic Cathinones: 4-chloromethcathinone, N-ethyl Pentedrone, and N-ethyl Hexedrone in Oral Fluid and Sweat of Consumers under Controlled Administration: Pilot Study.

11. Synthetic cannabinoids use in a sample of opioid-use disorder patients.

12. Targeted screening and quantification of synthetic cathinones and metabolites in hair by UHPLC-HRMS.

13. New Psychoactive Substances Consumption in Opioid-Use Disorder Patients.

14. Prevalence of Licit and Illicit Drugs Use during Pregnancy in Mexican Women.

15. Assessment of licit and illicit drugs consumption during pregnancy by Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry (UHPLC-HRMS) target screening in Mexican women hair.

16. New Synthetic Opioids Use among Patients in Treatment for an Opioid Use Disorder in Barcelona.

17. Clinical features and risk factors associated with prenatal exposure to drugs of abuse.

18. Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry and High-Sensitivity Gas Chromatography-Mass Spectrometry Screening of Classic Drugs and New Psychoactive Substances and Metabolites in Urine of Consumers.

19. Role of Neonatal Biomarkers of Exposure to Psychoactive Substances to Identify Maternal Socio-Demographic Determinants.

20. Determination of the Synthetic Cannabinoids JWH-122, JWH-210, UR-144 in Oral Fluid of Consumers by GC-MS and Quantification of Parent Compounds and Metabolites by UHPLC-MS/MS.

21. [Clinical features and risk factors associated with prenatal exposure to drugs of abuse].

22. UHPLC-HRMS and GC-MS Screening of a Selection of Synthetic Cannabinoids and Metabolites in Urine of Consumers.

23. Stability and Degradation Pathways of Different Psychoactive Drugs in Neat and in Buffered Oral Fluid.

25. Novel fast ultra-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) and extraction of ethylglucuronide in meconium samples.

26. Stability of cannabinoids in cannabis FM1 flowering tops and oil preparation evaluated by ultra-high performance liquid chromatography tandem mass spectrometry.

27. Dilute and shoot ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) analysis of psychoactive drugs in oral fluid.

29. The importance of biomarkers of fetal exposure to alcohol and psychotropic drugs in early diagnosis: A case report.

30. Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry.

31. Maternal hair testing to disclose self-misreporting in drinking and smoking behavior during pregnancy.

32. Intoxication caused by new psychostimulants: analytical methods to disclose acute and chronic use of benzofurans and ethylphenidate.

33. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry.

34. Chemsex intoxication involving sildenafil as an adulterant of GHB.

35. Ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) for determination of GHB, precursors and metabolites in different specimens: Application to clinical and forensic cases.

36. Method Development in Forensic Toxicology.

37. Analytical Strategies to Disclose Repeated Consumption of New Psychoactive Substances by Hair Analysis.

38. Identification and quantification of psychoactive drugs in whole blood using dried blood spot (DBS) by ultra-performance liquid chromatography tandem mass spectrometry.

39. Breast Milk and Hair Testing to Detect Illegal Drugs, Nicotine, and Caffeine in Donors to a Human Milk Bank.

40. Drugs of abuse in maternal hair and paired neonatal meconium: an objective assessment of foetal exposure to gestational consumption.

41. Segmental hair testing to disclose chronic exposure to psychoactive drugs.

42. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.

43. Fetal exposure to ethanol: relationship between ethyl glucuronide in maternal hair during pregnancy and ethyl glucuronide in neonatal meconium.

44. Ultra-high-pressure liquid chromatography tandem mass spectrometry determination of antidepressant and anxiolytic drugs in neonatal meconium and maternal hair.

45. Identification and quantification of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid glucuronide (THC-COOH-glu) in hair by ultra-performance liquid chromatography tandem mass spectrometry as a potential hair biomarker of cannabis use.

46. Ultra-high-pressure liquid chromatography tandem mass spectrometry determination of hallucinogenic drugs in hair of psychedelic plants and mushrooms consumers.

47. Rapid extraction, identification and quantification of drugs of abuse in hair by immunoassay and ultra-performance liquid chromatography tandem mass spectrometry.

48. Assessment of unsuspected exposure to drugs of abuse in children from a Mediterranean city by hair testing.

49. Testing ethylglucuronide in maternal hair and nails for the assessment of fetal exposure to alcohol: comparison with meconium testing.

50. Concentrations of atomoxetine and its metabolites in plasma and oral fluid from paediatric patients with attention deficit/hyperactivity disorder.

Catalog

Books, media, physical & digital resources